372 related articles for article (PubMed ID: 11956822)
1. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
4. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
[TBL] [Abstract][Full Text] [Related]
5. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
[TBL] [Abstract][Full Text] [Related]
6. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.
Ceballos KM; Nielsen GP; Selig MK; O'Connell JX
Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549
[TBL] [Abstract][Full Text] [Related]
7. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases.
Nicolas MM; Tamboli P; Gomez JA; Czerniak BA
Hum Pathol; 2010 May; 41(5):663-71. PubMed ID: 20004935
[TBL] [Abstract][Full Text] [Related]
8. [Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis].
Sun M; Liu JG; Weng QY; Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):87-93. PubMed ID: 29429158
[No Abstract] [Full Text] [Related]
9. Myofibroblastic differentiation in atypical fibroxanthomas occurring on sun-exposed skin and in a burn scar: an ultrastructural and immunohistochemical study.
Ito A; Yamada N; Yoshida Y; Morino S; Yamamoto O
J Cutan Pathol; 2011 Aug; 38(8):670-6. PubMed ID: 21623865
[TBL] [Abstract][Full Text] [Related]
10. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
[TBL] [Abstract][Full Text] [Related]
11. CD117 immunoreactivity in atypical fibroxanthoma.
Mathew RA; Schlauder SM; Calder KB; Morgan MB
Am J Dermatopathol; 2008 Feb; 30(1):34-6. PubMed ID: 18212542
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone.
Romeo S; Eyden B; Prins FA; Briaire-de Bruijn IH; Taminiau AH; Hogendoorn PC
J Pathol; 2006 Jan; 208(1):26-34. PubMed ID: 16278817
[TBL] [Abstract][Full Text] [Related]
13. Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.
Matsuyama A; Hisaoka M; Hashimoto H
Pathol Int; 2010 Mar; 60(3):212-6. PubMed ID: 20403047
[TBL] [Abstract][Full Text] [Related]
14. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
15. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.
Ueda T; Araki N; Mano M; Myoui A; Joyama S; Ishiguro S; Yamamura H; Takahashi K; Kudawara I; Yoshikawa H
J Clin Pathol; 2002 Nov; 55(11):853-8. PubMed ID: 12401825
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical distinction of cutaneous spindle cell carcinoma.
Morgan MB; Purohit C; Anglin TR
Am J Dermatopathol; 2008 Jun; 30(3):228-32. PubMed ID: 18496422
[TBL] [Abstract][Full Text] [Related]
17. Fibronexus in "malignant fibrous histiocytoma" of the bone: a case report of pleomorphic myofibrosarcoma.
Watanabe K; Ogura G
Ultrastruct Pathol; 2002; 26(1):47-51. PubMed ID: 12028659
[TBL] [Abstract][Full Text] [Related]
18. Characterization of smooth muscle cell and pericyte differentiation in the rat retina in vivo.
Hughes S; Chan-Ling T
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2795-806. PubMed ID: 15277506
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
20. A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle cell neoplasms.
Beck EM; Bauman TM; Rosman IS
J Cutan Pathol; 2018 Aug; 45(8):581-587. PubMed ID: 29687929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
